Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin

Oncogene

Volumn 22, Issue 9, 2003, Pages 1349-1357

  Chuang, Jih I ^a   Chang, Tsuey Y ^a   Liu, Hsiao S ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Glutathione; Ha ras; Melatonine; Reactive oxygen species

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; GLUTATHIONE SYNTHASE; HYDROGEN PEROXIDE; ISOPROPYL BETA DEXTRO THIOGALACTOSIDE; MELATONIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; THIOGLYCOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER; CANCER RECURRENCE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; FIBROBLAST; GENE OVEREXPRESSION; NONHUMAN; ONCOGENE H RAS; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; APOPTOSIS; BUTHIONINE SULFOXIMINE; CELL DIVISION; CELL LINE, TRANSFORMED; FREE RADICAL SCAVENGERS; GENES, RAS; GLUTATHIONE; GLUTATHIONE SYNTHASE; ISOPROPYL THIOGALACTOSIDE; MELATONIN; MICE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS P21(RAS); REACTIVE OXYGEN SPECIES; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SUPEROXIDES;

ANIMALIA;

EID: 0037422182     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206289     Document Type: Article

References (46)

1. Abe M, Reiter RJ, Orhii PB, Hara M and Poeggeler B. (1994). J. Pineal Res., 17, 94-100.
2. Agapito MT, Antolin Y, de Brio MT, Lopez-Burillo S, Pablos MI and Recio JM. (2001). J. Pineal Res., 31, 23-30.
3. Barranco SC, Perry RR, Durm ME, Quraishi M, Werner AL, Gregorcyk SG and Kolm P. (2000). Dis. Colon Rectum, 43, 1133-1140.
4. Beal MF. (1998). Biochim. Biophys. Acta, 1366, 211-223.
5. Blask DE, Wilson ST and Zalatan F. (1997). Cancer Res., 57, 1909-1914.
6. Chang MY, Won SJ, Yang BC, Jan MS and Liu HS. (1999). Exp. Cell Res., 248, 589-598.
7. Chen ST and Chuang JI. (1999). Exp. Brain Res., 124, 241-247.
8. Chen ST, Chuang JI, Hong MH and Li EI. (2002). J. Pineal Res., 32, 262-269.
9. Chuang JI, Chen ST, Chang YH and Jen LS. (2001). J. Chem. Neuroanat., 21, 215-223.
10. Cos S and Sanchez-Barcelo EJ. (2000). Front. Neuroendocrinol., 21, 133-170.
11. Granzotto M, Rapozzi V, DeCorte G and Giraidi T. (2001). J. Pineal Res., 31, 206-213.
12. Griffith OW. (1999). Free Radicals Biol. Med., 27, 922-935.
13. Guha A. (1998). Can. J. Neurol. Sci., 25, 267-281.
14. Guo N, McIntosh C and Shaw C. (1992). Neuroscience, 51, 835-842.
15. Irani K and Goldschmidt-Clermont PJ. (1998). Biochem. Pharmacol., 55, 1339-1346.
16. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T and Goldschmidt-Clermont PJ. (1997). Science, 275, 1649-1652.
17. Ito M. (1984). J. Interferon Res., 22, 603-608.
18. Joneson T, Bar-Sagi D. (1998). J. Biol. Chem., 273, 17991-17994.
19. Karbownik M, Lewinski A and Reiter RJ. (2001). Int. J. Biochem. Cell Biol., 33, 735-753.
20. Kilic E, Ozdemir YG, Bolay H, Kelestimur H and Dalkara T. (1999). J. Cerebr. Blood Flow Metab., 19, 511-516.
21. Kuo ML, Chou YW, Chau YP and Meng TC. (1996). Biochem. Pharmacol., 52, 481-488.
22. Li ZR, Reiter RJ, Fujimori O, Oh CS and Duan YP. (1997). J. Pineal Res., 22, 117-123.
23. Lissoni P. (1999). Melatonin in the Promotion of Health. Watson RR (ed). CRC press LLC: Boca Raton, FL, pp. 175-189.
24. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V and Maestroni G. (1996) Oncology, 53, 43-46.
25. Liu HS, Chen CY, Lee CH and Chou YI. (1998). Br. J. Cancer, 77, 1777-1786.
26. Marelli MM, Limonta P, Maggi R, Motta M and Moretti RM. (2000). Prostate, 45, 238-244.
27. Mayo JC, Sainz RM, Uría H, Antolín I, Estéban MM and Rodríguez C. (1998). J. Pineal Res., 25, 12-18.
28. Mediavilla MD, Cos S and Sánchez-Barceló EJ. (1999). Life Sci., 65, 415-420.
29. Meister A. (1994). Cancer Res. (Suppl.) 54, 1969s-1975s.
30. Miller AC, Gafner J, Clark EP and Samid D. (1993). Mol. Cell. Bio., 13, 4416-4422.
31. Neri B, Deleonardis V, Gemelli MT, Diloro F, Mottola A, Ponchietti R, Raugei A and Cini G. (1998). Anticancer Res., 18, 1329-1332.
32. Olanow CW. (1993). TINS, 16, 439-443.
33. Panzer A, Lottering ML, Bianchi P, Glencross DK, Stark JH, and Seegers JC. (1998). Cancer Lett., 122, 17-23.
34. Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC and Murphy E. (1999) J. Pineal Res., 26, 129-136.
35. Reiter RJ, Tan DX, Osuna C and Gitto E. (2000). J. Biomed. Sci., 7, 444-458.
36. Reiter RJ, Tan DX, Sainz RM and Mayo JC. (2002). Cardiovasc. Drugs Ther., 16, 5-6.
37. Roth JA, Rabin R and Agnello K. (1997). Brain Res., 768, 63-70.
38. Rothe G and Valet G. (1990). J. Leukocyte Biol., 47, 440-448.
39. Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG and Nussler AK. (2000). Cancer, 89, 1440-1447.
40. Seyfried J, Soldner F, Schulz JB, Klockgether T, Kovar KA and Wullner U. (1999) Neuroscience Lett., 264, 1-4.
41. Thrall BD and Meadows GG. (1991). Carcinogenesis, 12, 1319-1323.
42. Toffa S, Kunikowska GM, Zeng BY, Jenner P and Marsden CD. (1997). J. Neural Transm., 104, 67-75.
43. Vahrmeijer AL, Hoetelmans RW, Mulder GJ, Schytryps J, van Vilerberghe RL, van de Velde CJ and van Dierendonck JH. (2000). Biochem. Pharmacol., 59, 1557-1562.
44. Walsh AC and Lawrence DA. (1995). Cancer Lett., 95, 105-112.
45. Weijzen S, Velders MP and Kast WM. (1999) Leukemia, 13, 502-513.
46. Xu MF, Ho S, Qian ZM and Tang PL. (2001). J. Pineal Res., 31, 301-307.